血清AFP、β-hCG、uE3联合miR-146a-5p检测对孕中期唐氏综合征的筛查价值分析

doi:10.3969/j.issn.1001-8131.2024.03.005

Abstract
Figure/Table
References (0)
Related Citation (6)

Download: PDF (476 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze alpha fetoprotein（AFP）β- Human ch orionic gonadotropin（β- HCG）,free Estriol（uE3）and microRNA-146a-5p（miR-146a-5p）were used to screen Down's syndrome in the second trimester of pregnancy. Methods 53 pregnant women in the second trimester with positive results of Down's syndrome screening were divided into the observation group,and 64 healthy pregnant women in the second trimester who underwent physical examination at the same time were divided into the control group β-HCG,uE3,miR-146a-5p differences;Draw the receiver operating curve（ROC）and analyze the effectiveness of combined detection of AFP,β-hCG,uE3,and miR-146a-5p in screening for Down's syndrome. Results showed that the AFP and uE3 levels in the observation group were（20.53±2.81）μg/L and（1.46±0.34）ng/mL,respectively,lower than those in the control group（46.79±4.57）μg/L and（3.49±0.50）ng/mL,The β-hCG was（6.77±1.54）μg/L,and the miR-146a-5p was（3.24±0.67）,which was higher than the control group（3.15±0.63）μg/L and（1.25±0.31）,with a statistical difference（P<0.05）;ROC results display：The area under the curve（AUC）of AFP,β-hCG,uE3,and miR-146a-5p combined detection for Down's syndrome was 0.907（95% CI：0.848-0.967）,which was higher than the screened separately 0.740（95%CI：0.650-0.830）,0.844（95%CI：0.767-0.921）,0.822（95%CI：0.746-0.899）,and 0.839（95%CI：0.754-0.923）. Conclusion The combination of AFP,β-hCG,uE3,and miR-146a-5p can effectively screen for Down's syndrome in mid pregnancy,and has high practical value.

Key words： Down's syndrome Mid pregnancy Alpha fetoprotein β-Human chorionic gonadotropin

Received: 29 June 2023

PACS:

R715.3

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Gong Qianqian

Cite this article:

Gong Qianqian. Serum AFP β- Analysis of the Screening Value of hCG,uE3 Combined with miR-146a-5p Detection For Down's Syndrome in Mid Pregnancy[J]. journal1, 2024, 44(3): 14-16.

URL:

http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2024.03.005 OR http://www.hrbyybjb.org.cn/EN/Y2024/V44/I3/14

[1] 叶波,李红,廖志勇,等.血清ADAM12与PAPP-A水平检测在孕早中期唐氏综合征产前筛查诊断中的应用价值探究[J].中国优生与遗传杂志,2021,29(5):696-699.
[2] 沈鑫,董睿,翟卫斌,等.妊娠中期唐氏综合征筛查血清标志物水平与妊娠结局的关系[J].中国妇幼保健,2022,37(16):3069-3074.
[3] Pranpanus S,Keatkongkaew K,Suksai M.Utility of fetal facial markers on a second trimester genetic sonogram in screening for Down syndrome in a high-risk Thai population[J].BMC Pregnancy Childbirth,2022,22(1):27.
[4] Blanquet M,Dreux S,Léger S,et al.Cost-effectiveness threshold of first-trimester Down syndrome maternal serum screening for the use of cell-free DNA as a second-tier screening test[J].Ann Biol Clin(Paris),2021,79(4):331-338.
[5] 李凯音,张莉,孙远旭,等.孕11~13周超声NT检查联合血清PLGF、uE3筛查唐氏综合征[J].中国计划生育学杂志,2021,29(10):2204-2207,2252.
[6] 苏立,刘素娜,贾晨路,等.孕中期血清学检测联合超声NT筛查在唐氏综合征诊断中的应用价值[J].标记免疫分析与临床,2021,28(3):410-413.
[7] 王战勇,徐静,梁燕,等.孕中期血清唐氏综合征筛查与不良妊娠结局关联[J].基础医学与临床,2022,42(6):955-959.
[8] 朱若男,吴庆华,赵军红,等.无创DNA产前检测技术筛查唐氏综合征阳性结果的验证与分析[J].国际遗传学杂志,2021,44(1):1-5.
[9] 仲丽美,王英,李春妮,等.胎儿超声NT联合血清PIGF、ADAM12、uE3检测在唐氏综合征的早期预测中的价值分析[J].临床和实验医学杂志,2021,20(2):212-215.
[10] 罗静枝,缪铃,朱春兰,等.妊娠中期孕妇血清AFP、β-HCG、uE3、Inhibin-A联合检测预测不良妊娠结局价值[J].中国计划生育学杂志,2021,29(12):2671-2674.
[11] 冯迟,刘晓巍,王玥.孕中期唐氏筛查血清学指标对妊娠期高血压的预测价值分析[J].中华预防医学杂志,2021,55(6):747-751.
[12] 张丽珍,张丽红,钱荣华,等.血清学标志物联合NIPT对唐氏综合征的诊断价值[J].中国实验诊断学,2021,25(9):1360-1362.
[13] 姚胜萍,黄中秀,周显东,等.血清Inhibin-A、AFP、β-hCG、uE3联合无创DNA检测在孕中期唐氏综合征筛查效果[J].中国计划生育学杂志,2022,30(2):453-456
[14] 肖欢,张志安,梅军华,等.母体血清微RNA-146a-5p联合三联法检测在孕中期唐氏综合征筛查中的意义[J].安徽医药,2023,27(6):1231-1234.
[15] 王伟,张翠云,李金英,等.miR-146a-5p基因多态性与多囊卵巢综合征发病风险的相关性[J].中南医学科学杂志,2021,49(5):583-586.